

# About *The Journal of Clinical Endocrinology & Metabolism*

[Editor-in-Chief, Associate Editors, and Editorial Board](#)

[Author Guidelines](#)

[Aims and Scope](#)

[Journal Facts for \*The Journal of Clinical Endocrinology & Metabolism\*](#)

[Patient Access](#)

[Obligations of Editors](#)

[Advertising](#)

## Aims and Scope

---

*The Journal of Clinical Endocrinology & Metabolism* is the world's leading peer-reviewed journal for the dissemination of original research as it relates to the clinical practice of endocrinology, diabetes, and metabolism. Spanning the full spectrum of translational research from discovery science to experimental medicine and from critical evaluation of new treatments to patient-population-related outcomes, each issue provides up-to-date coverage of novel developments that enhance our understanding of the pathophysiology, diagnosis, and treatment of endocrine and metabolic disorders. JCEM also publishes articles that reveal insight into the metabolic-endocrine basis for, or treatment of, other human conditions including cardiovascular disease, cancer, and aging. Over and above new findings submitted from researchers across the globe, regular features of special interest include personal perspectives and commentaries on new developments, results of prismatic clinical trials, mini-reviews, and clinical practice guidelines.

JCEM will not consider:

- Articles that fall outside of the journal’s scope of “clinical practice of endocrinology, diabetes, and metabolism”
- Articles that contain exclusively animal or other pre-clinical data with no evidence of clinical translation
- Isolated association studies that fail to demonstrate impactful reach and significance. Association studies should validate or refute experimental data included within the same article.
- Mendelian Randomization studies that lack a clear mechanistic basis or fail to fully comply with the requirements of the STROBE-MR checklist (see [Author Guidelines](#))
- Research based mainly on self-reported patient data

## **Journal Facts for *The Journal of Clinical Endocrinology & Metabolism***

---

*Impact Factor 2024: 5.1*

[Scopus CiteScore tracker](#)

*Frequency of publication: Monthly*

*ISSN (print journal): 0021-972X*

*ISSN (online): 1945-7197*

*Discovery Resources: CABI, CINAHL, Clarivate, EBSCO, IFIS, OCLC, ProQuest/ExLibris, PubMed, TDNet, and Yewno*

*Ownership: Owned by the Endocrine Society, published under contract with Oxford University Press*

Our publishing partner, Oxford University Press (OUP), is a signatory of the [San Francisco Declaration on Research Assessment \(DORA\)](#), which is a world-wide initiative designed to improve the ways in which the outputs of scholarly research are evaluated. This includes reporting on a broader range of metrics. Find out more from OUP about the available metrics to assess both journals and individual articles [here](#).

## Contact

*The Journal of Clinical Endocrinology & Metabolism*

Endocrine Society

2055 L Street NW, Suite 600

Washington, DC 20036

Phone: 202-971-3669

[publications@endocrine.org](mailto:publications@endocrine.org)

## Patient Access

---

- Patients can request a copy of any article under access control. Please send the request to Member Services at [info@endocrine.org](mailto:info@endocrine.org). Please include the year, issue, page number, and title of the article.

## Obligations of Editors

---

- The Editor-in-Chief directs and supervises the policies of a journal and is responsible for maintaining its scientific and literary quality. The first obligation of an Editor-in-Chief and the journal's Associate Editors is to make certain that all authors receive confidential, expert, critical, and unbiased reviews of their work in a timely fashion. The editors and members of the editor's staff should not disclose any information about a manuscript submitted for review to anyone except the reviewers or authors or those working on their behalf.
- An editor may not take part in the editorial management of any report of the editor's own research because that involves conflict of interest. An editor must also avoid conflict of interest in the editorial management of reports of research closely related to the editor's own research.

- An editor may not use unpublished information of any kind from a submitted manuscript without written permission of the author.
- If an editor is presented with convincing evidence that the main substance or conclusions of a report published in an editor's journal is erroneous or determined to be the result of misconduct, the editor should facilitate prompt publication of a report pointing out the error and, if possible, correcting it. The report may be written by all the authors. For circumstances in which this is not possible, or there is disagreement, the Editor-in-Chief may consider the report written by some of the authors, academic or institutional sponsor, editor, or the Society.
- The Endocrine Society appreciates the importance of assuring unbiased authorship of editorials, reviews, and other non-research features involving selection of evidence to be discussed and perspectives to be presented. Consequently, special care is taken in choosing authors for such articles to assure their views are balanced and unencumbered, and that the Society's policies on disclosure of conflicts of interest are implemented.
- The Endocrine Society journals will refrain from publishing articles addressing political issues that are outside of either research funding or health care delivery. See the [Statement of Principle](#) for more information.

## Advertising

---

- All Endocrine Society Journals contain advertisements but advertising is not allowed to influence editorial decisions. Readers will be able to readily distinguish between editorial material and advertising. The juxtaposition of advertisements promoting specific products and scientific articles discussing such products is, as far as possible, avoided.
- The Endocrine Society and the editors do not provide unpublished advance information about journal content for forthcoming issues to agencies involved in soliciting advertisements or companies purchasing advertising space.

- The appearance of any advertisement does not imply warranty, endorsement, or approval of the products or services or of their effectiveness, quality, or safety by the Endocrine Society.
- The Society has the prerogative to reject any advertisement it deems inappropriate. It accepts advertisements only if the advertiser represents and warrants that its advertisement does not violate any applicable federal, state, or local laws.

### **Latest   Most Read   Most Cited**

Severity of MASH Activity by Iron-Corrected MRI Predicts Insulin Resistance and Cardiometabolic Risk in Type 2 Diabetes

Will Selective Androgen Receptor Modulators Ever Reach The Clinic?

Health and adverse events associated with extended oral bisphosphonates among postmenopausal women: a systematic review

Children born SGA receiving growth hormone have similarly impaired glucose-insulin metabolism as children with obesity

GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes